Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-blind, Randomized, Placebo-controlled, Multi-center, Fixed-dose, Parallel Group Efficacy and Safety in Pediatrics (6-17) With Attention-Deficit/Hyperactivity Disorder (ADHD) Using CTx-1301 (Dexmethylphenidate)

NCT05286762 is registered in ClinicalTrials.gov with Cingulate Therapeutics as lead sponsor.

NCT NCT05286762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05286762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multi-center, Fixed-dose, Parallel Group Efficacy and Safety in Pediatrics (6-17) With Attention-Deficit/Hyperactivity Disorder (ADHD) Using CTx-1301 (Dexmethylphenidate)
Lead sponsor
Cingulate Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
August 1, 2023
Completion date
February 29, 2024
Enrollment
103 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

adhd, adhd - combined type, attention deficit hyper activity, attention deficit hyperactivity disorder, attention deficit hyperactivity disorder combined, attention-deficit hyperactivity